Literature DB >> 11007134

Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease.

A Tran1, S Benzaken, M C Saint-Paul, E Guzman-Granier, P Hastier, C Pradier, E M Barjoan, N Demuth, F Longo, P Rampal.   

Abstract

OBJECTIVES: Chondrex (YKL-40) is a mammalian member of a protein family that includes bacterial chitinases. The pattern of its expression in certain tissues such as human liver or cartilage suggests a function in remodelling or degradation of extracellular matrix. The purpose of this study was to assess whether circulating YKL-40 might be a serum fibrosis marker in alcoholics.
METHODS: Plasma YKL-40 was determined in 146 consecutive heavy drinkers (106 men, 40 women; mean age, 49.2 +/- 9.0 years). Liver biochemical parameters and serum fibrosis markers such as hyaluronate were also measured. Fibrosis and inflammation in liver biopsy were evaluated using a semi-quantitative scoring system.
RESULTS: Plasma YKL-40 increased in parallel with the severity of fibrosis (P<0.00001). YKL-40 also increased in the presence of hepatic inflammation (P<0.01). Receiver operating characteristic curves of Chondrex revealed that a threshold of 330 microg/l gave a specificity of 88.5%; however, the sensitivity was only 50.8%. Only 11.5% of patients without severe fibrosis displayed a Chondrex plasma level above this threshold. A positive correlation was found between Chondrex and hyaluronate (r=0.40, P<0.0001), and a negative correlation was shown between Chondrex and the prothrombin index (r=-0.37, P<0.0001).
CONCLUSIONS: The severity of liver fibrosis is associated with elevated circulating Chondrex levels. The overlap in YKL-40 values prevents use of Chondrex in a screening programme. High levels of Chondrex (above 330 microg/l) are predictive of severe liver fibrosis. Increased plasma YKL-40 may reflect the remodelling of liver fibrosis in alcoholics.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11007134     DOI: 10.1097/00042737-200012090-00004

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  32 in total

Review 1.  Non-invasive diagnosis of liver fibrosis and cirrhosis.

Authors:  Yoav Lurie; Muriel Webb; Ruth Cytter-Kuint; Shimon Shteingart; Gerardo Z Lederkremer
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

2.  Non-invasive biomarkers for monitoring the fibrogenic process in liver: a short survey.

Authors:  Axel-M Gressner; Chun-Fang Gao; Olav-A Gressner
Journal:  World J Gastroenterol       Date:  2009-05-28       Impact factor: 5.742

3.  Non invasive tools for the diagnosis of liver cirrhosis.

Authors:  Maurizio Soresi; Lydia Giannitrapani; Melchiorre Cervello; Anna Licata; Giuseppe Montalto
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

Review 4.  Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy.

Authors:  Giada Sebastiani; Alfredo Alberti
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

5.  YKL-40 protein expression in normal adult human tissues--an immunohistochemical study.

Authors:  Merete Ringsholt; Estrid V S Høgdall; Julia S Johansen; Paul A Price; Lise H Christensen
Journal:  J Mol Histol       Date:  2007-01-23       Impact factor: 2.611

6.  Circulating YKL-40 levels during human endotoxaemia.

Authors:  J S Johansen; K S Krabbe; K Møller; B K Pedersen
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

Review 7.  Non-invasive diagnosis of alcoholic liver disease.

Authors:  Sebastian Mueller; Helmut Karl Seitz; Vanessa Rausch
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

Review 8.  Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease.

Authors:  Rosa Lombardi; Elena Buzzetti; Davide Roccarina; Emmanuel A Tsochatzis
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

9.  Human chitinases and chitinase-like proteins as indicators for inflammation and cancer.

Authors:  Julia Kzhyshkowska; Alexei Gratchev; Sergij Goerdt
Journal:  Biomark Insights       Date:  2007-05-03

10.  CHI3L1 Is a Liver-Enriched, Noninvasive Biomarker That Can Be Used to Stage and Diagnose Substantial Hepatic Fibrosis.

Authors:  Haijun Huang; Tiangang Wu; Jian Mao; Yongxing Fang; Jiajie Zhang; Lihua Wu; Shu Zheng; Biaoyang Lin; Hongying Pan
Journal:  OMICS       Date:  2015-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.